Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1021249 | 0.67 | CHEK1 (0.46) | ADORA3 | |
| SCHEMBL2442027 | 0.65 | ADORA3 (0.32) | ADORA3 | |
| SCHEMBL16636639 | 0.62 | ADORA3 (0.36) | ADORA3 | |
| SCHEMBL9215127 | 0.62 | MAPT (0.36) | ADORA3 | |
| SCHEMBL4403934 | 0.61 | RAB9A (0.44) | — | |
| SCHEMBL17459220 | 0.59 | ADORA3 (0.40) | ADORA3GRM5 | |
| SCHEMBL6469168 | 0.57 | ADORA3 (0.57) | ADORA3GRM5 | |
| SCHEMBL7011742 | 0.56 | ADORA3 (0.46) | ADORA3GRM5 | |
| SCHEMBL174735 | 0.56 | ADORA3 (1.00) | ADORA3GRM5 | |
| SCHEMBL7018068 | 0.56 | ADORA3 (0.55) | ADORA3GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3600312-B1 | PIPERIDINYL- AND PIPERAZINYL-SUBSTITUTED HETEROAROMATIC CARBOXAMIDES AS MODULATORS OF GPR6 | TAKEDA PHARMACEUTICALS CO (JP) | 2023-05-17 | — | — | EP | claimed |
| US-20200375969-A1 | PIPERIDINYL- AND PIPERAZINYL-SUBSTITUTED HETEROAROMATIC CARBOXAMIDES AS MODULATORS OF GPR6 | TAKEDA CALIFORNIA, INC. | 2020-12-03 | — | — | US | claimed |
| EP-0389352-B1 | 4-Fluoro-benzene derivatives, process for their preparation and pharmaceutical compositions containing these compounds | ADIR (FR) | 1994-04-13 | — | — | EP | claimed |
| US-5077288-A | Adrenergic, serotonin and histamine antagonist | ADIR ET COMPAGNIE (FR) | 1991-12-31 | — | — | US | claimed |
| EP-3600312-B1 | PIPERIDINYL- AND PIPERAZINYL-SUBSTITUTED HETEROAROMATIC CARBOXAMIDES AS MODULATORS OF GPR6 | TAKEDA PHARMACEUTICALS CO (JP) | 2023-05-17 | — | — | EP | disclosed |
| CN-110520127-B | Piperidinyl-substituted and piperazinyl-substituted heteroaromatic carboxamides as modulators of GPR6 | 武田药品工业株式会社 | 2023-05-16 | — | — | CN | disclosed |
| US-20220119361-A1 | 3-AMINO-4H-BENZO[E][1,2,4]THIADIAZINE 1,1-DIOXIDE DERIVATIVES AS INHIBITORS OF MRGX2 | SOLENT THERAPEUTICS, LLC | 2022-04-21 | — | — | US | disclosed |
| US-20200375969-A1 | PIPERIDINYL- AND PIPERAZINYL-SUBSTITUTED HETEROAROMATIC CARBOXAMIDES AS MODULATORS OF GPR6 | TAKEDA CALIFORNIA, INC. | 2020-12-03 | — | — | US | disclosed |
| WO-2020223255-A1 | 3-AMINO-4H-BENZO[E][1,2,4]THIADIAZINE 1,1-DIOXIDE DERIVATIVES AS INHIBITORS OF MRGX2 | SOLENT THERAPEUTICS, LLC (US) | 2020-11-05 | — | — | WO | disclosed |
| US-20200277262-A1 | N-(CYANO-SUBSTITUTED BENZYL OR PYRIDINYLMETHYL)-3-HYDROXYPICOLINAMIDE DERIVATIVES | JONES BENJAMIN (US) | 2020-09-03 | — | — | US | disclosed |
| EP-3676251-A1 | N-(CYANO-SUBSTITUTED BENZYL OR PYRIDINYLMETHYL)-3-HYDROXYPICOLINAMIDE DERIVATIVES USEFUL AS HIF PROLYL HYDROXYLASE INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2020-07-08 | — | — | EP | disclosed |
| WO-2019060850-A1 | N-(CYANO-SUBSTITUTED BENZYL OR PYRIDINYLMETHYL)-3-HYDROXYPICOLINAMIDE DERIVATIVES USEFUL AS HIF PROLYL HYDROXYLASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-03-28 | — | — | WO | disclosed |
| US-8492378-B2 | GSK-3β inhibitor | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-07-23 | — | — | US | disclosed |
| US-20100069381-A1 | GSK-3BETAINHIBITOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-18 | — | — | US | disclosed |
| US-5077288-A | Adrenergic, serotonin and histamine antagonist | ADIR ET COMPAGNIE (FR) | 1991-12-31 | — | — | US | disclosed |
| US-5077288-A | Adrenergic, serotonin and histamine antagonist | ADIR ET COMPAGNIE (FR) | 1991-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069381-A1 | GSK-3BETAINHIBITOR | GSK3B, GSK3A, GSKIP | ADORA3 1894/4885GRM5 2570/4885 |
| US-20200375969-A1 | PIPERIDINYL- AND PIPERAZINYL-SUBSTITUTED HETEROAROMATIC CARBOXAMIDES AS MODULATORS OF GPR6 | GPR6, GPR3, GPR68 | ADORA3 122/4885GRM5 76/4885 |
| US-20200277262-A1 | N-(CYANO-SUBSTITUTED BENZYL OR PYRIDINYLMETHYL)-3-HYDROXYPICOLINAMIDE DERIVATIVES | P4HA1, HRH3, HRH1 | ADORA3 783/4885GRM5 2502/4885 |
| US-20220119361-A1 | 3-AMINO-4H-BENZO[E][1,2,4]THIADIAZINE 1,1-DIOXIDE DERIVATIVES AS INHIBITORS OF MRGX2 | TPX2, MRGPRX2, CBX2 | ADORA3 990/4885GRM5 153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.